Ophthalmology · AIOS

Diabetic retinopathy

AIOS

Source:All India Ophthalmological Society Guidelines for Diabetic Retinopathy Screening (2023)AAO Diabetic Retinopathy Preferred Practice Pattern (2023)ICO Guidelines for Diabetic Eye Care (2023)

Verified Apr 2026

Ask House about this guideline

Red Flags

Sudden vision loss or new floaters with diabetes — emergency ophthalmology; vitreous haemorrhage or tractional retinal detachment^[1]
Severe non-proliferative diabetic retinopathy (NPDR), proliferative DR, or diabetic macular oedema — same-week retinal specialist for laser, intravitreal therapy, or vitrectomy^[1]
Pregnancy with pre-existing diabetes — screen for DR at booking and each trimester; risk of rapid worsening^[1]
Severe hypoglycaemia or rapid HbA1c reduction in T1DM with established DR — treatment-induced retinopathy worsening^[1]

First-line treatment

Interventions

Glycaemic, BP, lipid control^[1]
HbA1c <7% reduces progression by ~76% per UKPDS; BP <130/80; statin therapy; coordinate with diabetes physician
Annual screening pathway^[1]
Population-level screening with digital fundus photography or telemedicine; trained reader or AI grading; refer to ophthalmology for any DR more advanced than mild NPDR or any maculopathy
Pan-retinal photocoagulation (PRP)^[1]
Proliferative diabetic retinopathy; severe NPDR in selected high-risk patients; multiple sessions; transient peripheral vision loss
Intravitreal anti-VEGF therapy^[1]
Diabetic macular oedema (centre-involving); high-risk PDR alternative or adjunct to PRP; ranibizumab, bevacizumab (off-label, cost-effective in low-resource settings), aflibercept, faricimab
Vitrectomy^[1]
Non-clearing vitreous haemorrhage, tractional retinal detachment, fibrovascular proliferation; often combined with PRP and intraoperative anti-VEGF

First-line drug therapy

Drug	Class	Adult	Paediatric	Notes
Bevacizumab (intravitreal — off-label, cost-effective)^[1]	Anti-VEGF monoclonal antibody	1.25 mg intravitreal monthly × 5 doses then variable	—	Cost-effective alternative widely used in resource-limited settings; off-label for ophthalmic use; comparable efficacy in Protocol T for moderate vision loss
Ranibizumab (intravitreal)^[1]	Anti-VEGF Fab fragment	0.5 mg intravitreal injection monthly × 4–5 doses then variable (PRN, treat-and-extend)	—	First-line ophthalmic-licensed anti-VEGF for centre-involving DME; specialist administration; monitor IOP, endophthalmitis risk
Aflibercept (intravitreal)^[1]	Anti-VEGF fusion protein	2 mg intravitreal monthly × 5 doses then every 8 weeks	—	Comparable efficacy to ranibizumab; longer durability allowing extended intervals
Intravitreal triamcinolone or dexamethasone implant (refractory DME)^[1]	Intravitreal corticosteroid	Triamcinolone 4 mg intravitreal; dexamethasone 0.7 mg sustained-release implant every 4–6 months	—	Refractory DME or anti-VEGF non-response; cataract progression and IOP rise; consider after multiple anti-VEGF failures or pseudophakic eye

Bevacizumab (intravitreal — off-label, cost-effective)^[1]

Anti-VEGF monoclonal antibody

Adult: 1.25 mg intravitreal monthly × 5 doses then variable
Paediatric: —

Cost-effective alternative widely used in resource-limited settings; off-label for ophthalmic use; comparable efficacy in Protocol T for moderate vision loss

Ranibizumab (intravitreal)^[1]

Anti-VEGF Fab fragment

Adult: 0.5 mg intravitreal injection monthly × 4–5 doses then variable (PRN, treat-and-extend)
Paediatric: —

First-line ophthalmic-licensed anti-VEGF for centre-involving DME; specialist administration; monitor IOP, endophthalmitis risk

Aflibercept (intravitreal)^[1]

Anti-VEGF fusion protein

Adult: 2 mg intravitreal monthly × 5 doses then every 8 weeks
Paediatric: —

Comparable efficacy to ranibizumab; longer durability allowing extended intervals

Intravitreal triamcinolone or dexamethasone implant (refractory DME)^[1]

Intravitreal corticosteroid

Adult: Triamcinolone 4 mg intravitreal; dexamethasone 0.7 mg sustained-release implant every 4–6 months
Paediatric: —

Refractory DME or anti-VEGF non-response; cataract progression and IOP rise; consider after multiple anti-VEGF failures or pseudophakic eye

Safety-net

Annual eye check is essential even when vision feels normal — diabetic retinopathy is silent until advanced^[1]
Sudden vision loss, new floaters, flashes, or sudden blurry vision — same-day ophthalmology assessment^[1]
Tight blood sugar and BP control slows progression; coordinate rapid HbA1c reductions with eye team^[1]

Referral criteria

Any DR more advanced than mild NPDR; any diabetic macular oedemaOphthalmology / retina specialist^[1]
Sudden vision loss, vitreous haemorrhage, tractional retinal detachment, neovascular glaucomaEmergency ophthalmology^[1]
Pregnancy with pre-existing diabetesScreen at booking and trimester progression^[1]
Failure of anti-VEGF or refractory DMETertiary retinal service for combined therapy or alternative agent^[1]

Clinical summary

Screening, staging, anti-VEGF, laser, and surgical pathway for diabetic retinopathy and diabetic macular oedema in adults with diabetes.

References

1.All India Ophthalmological Society Guidelines for Diabetic Retinopathy Screening (2023); AAO Diabetic Retinopathy Preferred Practice Pattern; ICO Guidelines for Diabetic Eye Care (2023)

Drug

Class

Adult

Paediatric

Notes